Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma
Authors
- Ke Yang (ORCID: https://orcid.org/0000-0002-1870-1134)
- Jiadai Xu (ORCID: https://orcid.org/0000-0001-6480-5607)
- Yuhong Ren (ORCID: https://orcid.org/0000-0003-0330-4125)
- Jing Li (ORCID: https://orcid.org/0000-0001-7986-0078)
- Peng Liu (ORCID: https://orcid.org/0000-0002-9639-6606)
- Yue Wang (ORCID: https://orcid.org/0000-0001-6936-5081)
- Ling Yuan (ORCID: https://orcid.org/0000-0001-6921-2165)
- Wei‐Guang Wang (ORCID: https://orcid.org/0000-0003-3395-767X)
- Zhixiang Cheng (ORCID: https://orcid.org/0009-0002-0984-4771)
- Xuejiao Zhang (ORCID: https://orcid.org/0000-0001-9544-0073)
- Luya Cheng
- Jingli Zhuang
Institutions
- Fudan University (CN)
- Zhongshan Hospital (CN)